22.97
-0.69 (-2.92%)
| Previous Close | 23.66 |
| Open | 23.55 |
| Volume | 587,496 |
| Avg. Volume (3M) | 721,455 |
| Market Cap | 1,186,618,240 |
| Price / Earnings (Forward) | 94.34 |
| Price / Sales | 3.33 |
| Price / Book | 4.30 |
| 52 Weeks Range |
| Profit Margin | 17.92% |
| Operating Margin (TTM) | -9.46% |
| Diluted EPS (TTM) | 1.12 |
| Quarterly Revenue Growth (YOY) | 17.50% |
| Total Debt/Equity (MRQ) | 7.98% |
| Current Ratio (MRQ) | 4.11 |
| Operating Cash Flow (TTM) | 26.78 M |
| Levered Free Cash Flow (TTM) | 29.89 M |
| Return on Assets (TTM) | -5.20% |
| Return on Equity (TTM) | 19.54% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | CareDx, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | 1.5 |
| Price Volatility | -4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 1.10 |
|
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Core |
| % Held by Insiders | 3.22% |
| % Held by Institutions | 99.39% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BICKERSTAFF GEORGE | 22.97 | - | 9,795 | 224,991 |
| COHEN FRED E | 22.97 | - | 9,795 | 224,991 |
| COURNOYER CHRISTINE | 22.97 | - | 9,795 | 224,991 |
| GOLDBERG MICHAEL | 22.97 | - | 9,795 | 224,991 |
| GUNASEKARAN SURESH | 22.97 | - | 9,795 | 224,991 |
| HANNA JOHN WALTER JR | - | 23.87 | -39,681 | -946,279 |
| RIGGSBEE RICHARD BRYAN | 22.97 | - | 9,795 | 224,991 |
| VALANTINE HANNAH | 22.97 | 24.08 | -2,308 | -66,449 |
| Aggregate Net Quantity | 16,781 | |||
| Aggregate Net Value ($) | 337,218 | |||
| Aggregate Avg. Buy ($) | 22.97 | |||
| Aggregate Avg. Sell ($) | 23.94 | |||
| Insider Range ($) | ||||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| VALANTINE HANNAH | Director | 15 Jun 2026 | Automatic sell (-) | 12,103 | 24.08 | 291,440 |
| HANNA JOHN WALTER JR | Officer | 15 Jun 2026 | Automatic sell (-) | 17,683 | 24.08 | 425,807 |
| GOLDBERG MICHAEL | Director | 12 Jun 2026 | Acquired (+) | 9,795 | 22.97 | 224,991 |
| BICKERSTAFF GEORGE | Director | 12 Jun 2026 | Acquired (+) | 9,795 | 22.97 | 224,991 |
| GUNASEKARAN SURESH | Director | 12 Jun 2026 | Acquired (+) | 9,795 | 22.97 | 224,991 |
| COHEN FRED E | Director | 12 Jun 2026 | Acquired (+) | 9,795 | 22.97 | 224,991 |
| RIGGSBEE RICHARD BRYAN | Director | 12 Jun 2026 | Acquired (+) | 9,795 | 22.97 | 224,991 |
| COURNOYER CHRISTINE | Director | 12 Jun 2026 | Acquired (+) | 9,795 | 22.97 | 224,991 |
| VALANTINE HANNAH | Director | 12 Jun 2026 | Acquired (+) | 9,795 | 22.97 | 224,991 |
| HANNA JOHN WALTER JR | Officer | 11 Jun 2026 | Automatic sell (-) | 21,998 | 23.66 | 520,473 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |